Security key
09074F405
BIOVIE INC. - Class A Common Stock, par value $0.0001 per share (BIVI)
CUSIP: 09074F405
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Class A Common Stock, par value $0.0001 per share
- Total 13F shares
- 756,205
- Total 13F value
- $1,518,258
- Share change
- +591,849
- SEC-reported price per share
- $2.00
- Number of holders
- 43
- Value change
- +$1,200,439
- Number of buys
- 27
- Number of sells
- 10
- Shares outstanding
- 7,932,763
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
43
Top holders
10
BIVI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
BIOVIE INC. SEC filings
BIOVIE INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09074F405
Recent filing periods:
Ownership snapshot
Top reported holders of BIVI - BIOVIE INC. - Class A Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Terren S. Peizer
Disclosed value leader
Jonathan M. Adams
Comparable rows
0/15
Latest evidence
20 Nov 2024
3/4/5
13F
Highest disclosed value: $82,185
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Jonathan M. Adams has the largest disclosed position value at $82.2K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Jonathan M. Adams's linked filing trail.
Disclosed position value
Top 5
Jonathan M. Adams
$82.2K
Penelope Markham
$80.9K
Steve Gorlin
$78.3K
VANGUARD GROUP INC
$68.2K
Christopher Reading
$62.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Terren S. Peizer |
3/4/5
Director, 10%+ Owner
|
—
denominator unverified
|
—
65,000 shares
|
— | 23 Nov 2022 |
| Jonathan M. Adams |
3/4/5
EVP Liver Cirrhosis Programs
|
—
denominator unverified
|
$82,185
48,630 shares
|
— | 02 Feb 2022 |
| Penelope Markham |
3/4/5
EVP Liver Cirrhosis R&D
|
—
denominator unverified
|
$80,851
47,841 shares
|
— | 16 Feb 2023 |
| Steve Gorlin |
3/4/5
Director
|
—
denominator unverified
|
$78,345
46,358 shares
|
— | 09 Nov 2023 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$68,205
56,837 shares
|
— | 30 Sep 2024 |
| Christopher Reading |
3/4/5
EVP Neuroscience R&D
|
—
denominator unverified
|
$62,780
37,148 shares
|
— | 16 Feb 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
43
Shares
756,205
Rows available
43
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2025 Across Filers
Q3 2025 holders
2
Q4 2024 holders
43
Holder diff
41
| Investor | Q3 2025 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend